- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Hospital formulary manager complained about AstraZeneca rep’s conduct promoting Crestor after D&TC rejection. Panel found insufficient evidence of misconduct or failure to…
ProStrakan was found in breach for a sponsored “Advertisement Feature” promoting Rectogesic online without prescribing information and with an SPC-inconsistent treatment algorithm,…
UK employee ‘likes’ of a US LinkedIn post were treated as proactive UK dissemination. Breaches upheld for pre-authorisation promotion and lack of…
PMCPA queried whether a free stethoscope offered to GPs breached the £6 cost/perceived value limits for promotional aids. The Panel found it…
Johnson & Johnson alleged Baxter promoted Tisseel beyond its licence (eg burns/plastics). Panel found the materials and activity were not inconsistent with…
Ipsen complained about Allergan’s promotion of Vistabel. The PMCPA recorded no breach because the matter was outwith the scope of the ABPI…
Complaint about a health professional letter regarding Cipramil. PMCPA recorded no breach because the matter was outwith the scope of the ABPI…
Lundbeck’s UK product webpage was ruled to advertise POMs to the public, and multiple Abilify Maintena co-promotion materials were not certified in…
Complaint alleged a Shire video was on a public website. The case was completed with no breach and found to be outwith…
Complaint about Ozempic promotion and formulary support. Most allegations not proven, but Novo Nordisk breached Clause 7.9 and 9.1 after a formulary…
PMCPA found ViiV’s ViiV Exchange landing page was aimed at HCPs but did not sufficiently direct patients/public to appropriate sections, making access…
A BMJ hosted-content “tile” promoting Otezla lacked a clear single-click link to prescribing information and appeared not to be separately certified. Breaches…
A Kisqali leaflet used at a breast cancer meeting was ruled misleading for not making clear OS data applied to the aromatase…
Complaint alleged a third-party email showed “client product/therapy priorities” bias in a Takeda-sponsored T2DM therapy review. Panel and Appeal Board had concerns…
Renocontin promo implied an 80mg tablet existed via a cost table and bioequivalence claim, and used outdated prescribing information after an SPC…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.